ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.

Eric M Jurgens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.